1. Orphanet J Rare Dis. 2018 Jan 25;13(1):20. doi: 10.1186/s13023-017-0725-y.

The progression rate of spinocerebellar ataxia type 2 changes with stage of 
disease.

Monte TL(1)(2), Reckziegel EDR(3), Augustin MC(3), Locks-Coelho LD(3), Santos 
ASP(3), Furtado GV(4)(5), de Mattos EP(4)(5), Pedroso JL(6), Barsottini OP(6), 
Vargas FR(7)(8)(9), Saraiva-Pereira ML(10)(4)(11)(5), Camey SA(12)(13)(14), 
Leotti VB(13)(14), Jardim LB(15)(16)(17)(18)(19)(20)(21); Rede Neurogenética.

Author information:
(1)Serviço de Neurologia, Hospital de Clínicas de Porto Alegre, Porto Alegre, 
Rio Grande do Sul, Brazil.
(2)Programa de Pós-Graduação em Ciências Médicas, Universidade Federal do Rio 
Grande do Sul, Porto Alegre, Brazil.
(3)Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto 
Alegre, Brazil.
(4)Laboratório de Identificação Genética, Hospital de Clínicas de Porto Alegre, 
Porto Alegre, Rio Grande do Sul, Brazil.
(5)Programa de Pós-Graduação em Genética e Biologia Molecular, Universidade 
Federal do Rio Grande do Sul, Porto Alegre, Brazil.
(6)Setor de Neurologia Geral e Ataxias. Disciplina de Neurologia Clínica da 
UNIFESP - Escola Paulista de Medicina, Universidade Federal de São Paulo, São 
Paulo, Brazil.
(7)Laboratório de Epidemiologia de Malformações Congênitas, Fundação Oswaldo 
Cruz, Rio de Janeiro, Brazil.
(8)Departamento de Genética e Biologia Molecular, Universidade Federal do Estado 
do Rio de Janeiro, Rio de Janeiro, Brazil.
(9)Instituto Nacional de Genética Médica Populacional, Rio de Janeiro, Brazil.
(10)Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre, Rua Ramiro 
Barcelos 2350, Porto Alegre, Rio Grande do Sul, 90.035-903, Brazil.
(11)Departamento de Bioquímica, Universidade Federal do Rio Grande do Sul, Porto 
Alegre, Brazil.
(12)Grupo de Pesquisa e Pós-Graduação Hospital de Clínicas de Porto Alegre, 
Porto Alegre, Brazil.
(13)Departamento de Estatística, Universidade Federal do Rio Grande do Sul, 
Porto Alegre, Brazil.
(14)Programa de Pós-Graduação em Epidemiologia, Universidade Federal do Rio 
Grande do Sul, Porto Alegre, Brazil.
(15)Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre, Rua Ramiro 
Barcelos 2350, Porto Alegre, Rio Grande do Sul, 90.035-903, Brazil. 
ljardim@hcpa.edu.
(16)Laboratório de Identificação Genética, Hospital de Clínicas de Porto Alegre, 
Porto Alegre, Rio Grande do Sul, Brazil. ljardim@hcpa.edu.
(17)Departamento de Medicina Interna, Universidade Federal do Rio Grande do Sul, 
Porto Alegre, Brazil. ljardim@hcpa.edu.
(18)Programa de Pós-Graduação em Ciências Médicas, Universidade Federal do Rio 
Grande do Sul, Porto Alegre, Brazil. ljardim@hcpa.edu.
(19)Programa de Pós-Graduação em Genética e Biologia Molecular, Universidade 
Federal do Rio Grande do Sul, Porto Alegre, Brazil. ljardim@hcpa.edu.
(20)Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto 
Alegre, Brazil. ljardim@hcpa.edu.
(21)Instituto Nacional de Genética Médica Populacional, Rio de Janeiro, Brazil. 
ljardim@hcpa.edu.

BACKGROUND: Spinocerebellar ataxia type 2 (SCA2) affects several neurological 
structures, giving rise to multiple symptoms. However, only the natural history 
of ataxia is well known, as measured during the study duration. We aimed to 
describe the progression rate of ataxia, by the Scale for the Assessment and 
Rating of Ataxia (SARA), as well as the progression rate of the overall 
neurological picture, by the Neurological Examination Score for Spinocerebellar 
Ataxias (NESSCA), and not only during the study duration but also in a disease 
duration model. Comparisons between these models might allow us to explore 
whether progression is linear during the disease duration in SCA2; and to look 
for potential modifiers.
RESULTS: Eighty-eight evaluations were prospectively done on 49 symptomatic 
subjects; on average (SD), study duration and disease duration models covered 13 
(2.16) months and 14 (6.66) years of individuals' life, respectively. SARA 
progressed 1.75 (CI 95%: 0.92-2.57) versus 0.79 (95% CI 0.45 to 1.14) 
points/year in the study duration and disease duration models. NESSCA progressed 
1.45 (CI 95%: 0.74-2.16) versus 0.41 (95% CI 0.24 to 0.59) points/year in the 
same models. In order to explain these discrepancies, the progression rates of 
the study duration model were plotted against disease duration. Then an 
acceleration was detected after 10 years of disease duration: SARA scores 
progressed 0.35 before and 2.45 points/year after this deadline (p = 0.013). Age 
at onset, mutation severity, and presence of amyotrophy, parkinsonism, dystonic 
manifestations and cognitive decline at baseline did not influence the rate of 
disease progression.
CONCLUSIONS: NESSCA and SARA progression rates were not constant during disease 
duration in SCA2: early phases of disease were associated with slower 
progressions. Modelling of future clinical trials on SCA2 should take this 
phenomenon into account, since disease duration might impact on inclusion 
criteria, sample size, and study duration. Our database is available online and 
accessible to future studies aimed to compare the present data with other 
cohorts.

DOI: 10.1186/s13023-017-0725-y
PMCID: PMC5785809
PMID: 29370806 [Indexed for MEDLINE]

Conflict of interest statement: ETHICS APPROVAL AND CONSENT TO PARTICIPATE: The 
study protocol was approved by the institutional ethical committees of the 
contributing centers (registered as 12–0346 at Comissao de Etica em Pesquisa of 
our institution, and as 07105712.1.0000.5327 at the Brazilian National platform, 
Plataforma Brasil). All patients gave written informed consent to participate in 
the study. CONSENT FOR PUBLICATION: Not applicable – this report does not 
contain any individual persons data. COMPETING INTERESTS: The authors declare 
that they don’t have conflict of interest. PUBLISHER’S NOTE: Springer Nature 
remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.